CONMED Corporation (CNMD) Stock Analysis

The top 5 analyst questions from CONMED’s Q3 earnings call

Sat, October 31, 2026 at 7:39 PM UTC 4 min read

CONMED's Q3 earnings report showed stable performance, with revenue of $335.6 million meeting expectations and adjusted EPS of $1.04 exceeding estimates. CEO Patrick J. Beyer highlighted strong international growth and contributions from key products like AirSeal, despite soft domestic orthopedic sales due to ongoing reorganization. The company reaffirmed its full-year revenue guidance of $1.36 billion and slightly raised its adjusted EPS guidance to $4.58, while analysts raised questions about revenue guidance, domestic sales recovery, and international product rollout.

Read full article →

CONMED Corporation Q3 2026 Earnings Call Summary

Thu, October 29, 2026 at 12:30 PM UTC 2 min read

CONMED Corporation reported its Q3 2026 earnings, showcasing a significant increase in revenue driven by strong demand for its surgical devices and innovative product launches. The company’s improved financial performance highlights its competitive position in the medical technology sector, which is crucial for investors seeking growth opportunities. Additionally, management's positive outlook for the upcoming quarters suggests continued momentum, making CNMD an attractive option for those looking to invest in healthcare innovation.

Read full article →